MAP2K1 and osteoporosis: Importantly, FCL showed strong binding activities to the cathepsin K and mitogen-activated proteinkinase kinase 1 (MEK1), which indicated that FCL may possess anti-osteoporosis potentials targeting cathepsin K and MEK1.